Want to see AU:EMV full AI Analyst Report?
Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$2.00
▲(16.28% Upside)
Action:Reiterated
Date:08/26/26
The score is primarily constrained by weak financial performance: zero revenue in 2026, sustained losses, and ongoing free cash flow burn. Technicals are a partial offset, with the share price above major moving averages and positive MACD indicating constructive momentum. Valuation remains a secondary drag because negative earnings (negative P/E) reduces the usefulness of traditional valuation signals and no dividend yield is available.
Positive Factors
Portable point-of-care imaging
A portable system designed for point-of-care use could address workflow limitations of conventional brain imaging, supporting faster clinical decisions and broadening access across ambulances, emergency departments, and bedside settings if development and validation succeed.
Negative Factors
Revenue disruption
The collapse to zero revenue indicates that the prior revenue base was not yet durable or that commercialization has been disrupted. Until recurring sales are demonstrated, forecasting growth, validating demand, and funding operations remain difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Portable point-of-care imaging
A portable system designed for point-of-care use could address workflow limitations of conventional brain imaging, supporting faster clinical decisions and broadening access across ambulances, emergency departments, and bedside settings if development and validation succeed.
Read all positive factors
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$174.76M
Dividend YieldN/A
Average Volume (3M)33.13K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS Growth20.40%
CountryAU
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding92,955,560
10 Day Avg. Volume39,945
30 Day Avg. Volume33,128
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)8.78
Price to Sales (P/S)0.00
P/FCF Ratio-21.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside83.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.11
Revenue Forecast (FY)AU$5.00M
EMvision Medical Devices Ltd. Business Overview & Revenue Model
Company Description
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile bra...
How the Company Makes Money
null...
EMvision Medical Devices Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.05M | 11.22M | 6.97M | 4.36M |
| Gross Profit | -416.90K | 5.05M | 11.22M | 6.63M | 4.12M |
| EBITDA | -16.51M | -8.71M | -8.35M | -5.99M | -7.84M |
| Net Income | -8.32M | -9.81M | -2.73M | -3.87M | -6.11M |
Balance Sheet | |||||
| Total Assets | 23.04M | 15.57M | 23.97M | 11.52M | 8.51M |
| Cash, Cash Equivalents and Short-Term Investments | 17.10M | 10.53M | 18.67M | 9.97M | 6.80M |
| Total Debt | 3.41M | 3.53M | 2.90M | 3.04M | 737.86K |
| Total Liabilities | 7.27M | 6.29M | 5.46M | 6.40M | 1.43M |
| Stockholders Equity | 15.77M | 9.28M | 18.52M | 5.12M | 7.08M |
Cash Flow | |||||
| Free Cash Flow | -6.37M | -7.89M | -6.29M | 646.86K | -3.97M |
| Operating Cash Flow | -6.25M | -7.84M | -5.99M | 834.15K | -3.78M |
| Investing Cash Flow | -124.22K | -50.37K | -302.41K | -187.29K | -191.12K |
| Financing Cash Flow | 13.02M | -258.34K | 15.00M | 2.52M | 1.08M |
EMvision Medical Devices Ltd. Technical Analysis
Positive
1.72
Price Trends
1.65
Positive
1.68
Positive
1.71
Positive
Market Momentum
0.04
Negative
66.45
Neutral
81.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMV, the sentiment is Positive. The current price of 1.72 is below the 20-day moving average (MA) of 1.76, above the 50-day MA of 1.65, and above the 200-day MA of 1.71, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.45 is Neutral, neither overbought nor oversold. The STOCH value of 81.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EMV.
EMvision Medical Devices Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$49.94M | 227.27 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$174.76M | -20.59 | -46.84% | ― | ― | 20.40% | |
46 Neutral | AU$2.17B | -9.13 | -288.42% | ― | 20.64% | -457.40% | |
44 Neutral | AU$32.04M | -2.98 | -103.48% | ― | -22.43% | 15.02% | |
43 Neutral | AU$21.82M | -2.95 | -201.54% | ― | -100.00% | 50.49% | |
42 Neutral | AU$65.38M | -3.25 | -62.14% | 0.64% | 12.05% | -31.71% |
* Healthcare Sector Average
AU:EMV
EMvision Medical Devices Ltd.
1.88
-0.10
-5.05%
AU:CMP
Compumedics Limited
0.25
-0.07
-20.63%
AU:NTI
Neurotech International
0.01
>-0.01
-13.33%
AU:CYC
Cyclopharm Limited
0.52
-0.36
-40.91%
AU:CBL
Control Bionics Ltd.
0.06
0.02
63.89%
AU:4DX
4DMedical Ltd
3.60
1.29
55.84%
EMvision Medical Devices Ltd. Corporate Events
EMVision updates registered office without operational changes
Aug 23, 2026
EMVision Medical Devices Ltd has updated its registered office address to Suite 4.01, 65 Epping Road, Macquarie Park, NSW 2113, effective immediately. The company emphasised that its principal place of business and all other contact details remain...
EMVision Advances Pivotal Brain Scanner Trial and Strengthens Funding Base
Jul 14, 2026
EMVision reported strong progress in its pivotal validation trial for the emu™ point-of-care brain scanner, surpassing key enrolment milestones across U.S. and Australian hospitals and integrating smoothly into code stroke workflows. The tri...
EMVision Secures Nature-Portfolio Validation for AI Stroke Scanner
Jul 14, 2026
EMVision’s EMView study, using its emu™ RF brain scanner and proprietary deep-learning models, has been published in npj Digital Medicine, offering peer-reviewed validation of the platform and its AI methods. The research highlights st...
EMVision aeromedical trial de-risks rural stroke scanner deployment
May 26, 2026
EMVision Medical Devices has completed a feasibility and usability study of its First Responder Brain Scanner in an aeromedical retrieval setting with the Royal Flying Doctor Service, the Australian Stroke Alliance and the South Australian Ambulan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.